Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 18;11(12):1941-1944.
doi: 10.18240/ijo.2018.12.11. eCollection 2018.

XEN® implant and trabeculectomy medium-term quality of life assessment and comparison of results

Ana Luísa Basílio  1 , Nuno Moura-Coelho  1 , Inês Passos  1 , Mariana Sá Cardoso  1 , Isabel Domingues  1 , Maria Reina  1 , Rita Flores  1 , Teresa Gomes  1
Affiliations

XEN® implant and trabeculectomy medium-term quality of life assessment and comparison of results

Ana Luísa Basílio et al. Int J Ophthalmol. .

Abstract

Aim: To evaluate and compare the quality of life of patients submitted to XEN® implant or trabeculectomy and the relationship with potentially involved variables.

Methods: A cross-sectional study of patients with advanced open-angle glaucoma who underwent implantation of XEN® (group 1) and trabeculectomy (group 2) between October 2015 and February 2017. The studied variables were: age, gender, follow-up time, need of topical anti-hypertensive therapy, visual acuity and intraocular pressure (IOP). The quantification of the quality of life was attained through the Glaucoma Symptom Scale (GSS) questionnaire.

Results: Totally 34 eyes (34 patients) were included, 17 in each group. The mean GSS scores for group 1 were 42.6±6.8 (median, 47; p25, 36.5; p75, 48.5) and for group 2 it was 41.6±7.0 (median, 43; p25, 36.5; p75, 47.0; P=0.34). There was a strong negative correlation between the need for topical anti-hypertensive drugs and the GSS result in both groups (r=-0.88, P<0.01, r=-0.59, P=0.01, respectively) and a moderate negative correlation with IOP in group 1 (r=-0.50, P=0.03).

Conclusion: The analysis demonstrates the non-inferiority of medium-term quality of life of one group in relation to the other (XEN® implant and trabeculectomy). The number of topical anti-hypertensive drugs and IOP negatively influenced the quality of life.

Keywords: XEN®; quality of life; trabeculectomy.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Quaranta L, Riva I, Gerardi C, Oddone F, Floriano I, Konstas AGP. Quality of life in glaucoma: a review of the literature. Adv Ther. 2016;33(6):959–981. - PMC - PubMed
    1. Black N. Patient reported outcome measures could help transform healthcare. BMJ. 2013;346:f167–f167. - PubMed
    1. Kotecha A, Feuer WJ, Barton K, Gedde SJ. Quality of life in the tube versus trabeculectomy study. Am J Ophthalmol. 2017;176:228–235. - PubMed
    1. Hirneiss C, Kortüm K. Quality of life in patients with glaucoma. Klin Monbl Augenheilkd. 2016;233(2):148–153. - PubMed
    1. Burr J, Azuara-Blanco A, Avenell A, Tuulonen A. Medical versus surgical interventions for open angle glaucoma. Cochrane Database Syst Rev. 2012;(9):CD004399. - PubMed

LinkOut - more resources